Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Picard Medical, Inc. ( (PMI) ) just unveiled an update.
On March 19, 2026, Picard Medical highlighted a UCSF Health case in which a male patient in his twenties with advanced biventricular heart failure was implanted with the SynCardia Total Artificial Heart on November 15, 2025. After 119 days of support as a bridge to transplant, the patient successfully underwent heart transplantation on March 14, 2026.
This case was the second of five UCSF patients successfully bridged to transplant with SynCardia’s system, underscoring growing clinical adoption of total artificial heart therapy at major transplant centers. The outcome reinforces SynCardia’s position in the advanced heart failure market as demand rises for mechanical circulatory support solutions that can sustain critically ill patients while they wait for scarce donor organs.
The most recent analyst rating on (PMI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.
Spark’s Take on PMI Stock
According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.
The score is held down mainly by very weak fundamentals (large ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates and financing improve near-term runway and visibility, but do not yet offset the current profitability and cash-flow risks.
To see Spark’s full report on PMI stock, click here.
More about Picard Medical, Inc.
Picard Medical, Inc., listed on the NYSE American, is the parent of Tucson-based SynCardia Systems, which develops, manufactures, and commercializes the SynCardia Total Artificial Heart for patients with end-stage biventricular heart failure. SynCardia’s device is the first total artificial heart approved by both the U.S. FDA and Health Canada and remains the only commercially available artificial heart in the United States and Canada, with more than 2,100 implants performed at hospitals in 27 countries.
Positioned as a leader in advanced mechanical circulatory support, the company targets leading transplant centers and high-acuity heart failure programs that require bridge-to-transplant solutions. Its SynCardia Total Artificial Heart assumes full circulatory function in patients with failing or failed hearts, underscoring its strategic role in addressing the growing global demand for lifesaving heart replacement technologies.
Average Trading Volume: 814,043
Technical Sentiment Signal: Strong Sell
For an in-depth examination of PMI stock, go to TipRanks’ Overview page.